Motley Fool Again
Healthy momentum Next up we have Viemed Healthcare (TSX:VMD), which managed to reach a 52-week high of $8.75 last week. Shares of the healthcare equipment specialist have gained a whopping 228% year to date, while the S&P/TSX Capped Health Care Index is up 36% over the same time period.
Viemed is adding patients to its therapy at a breakneck pace. In Q2, revenue spiked 42% to $15.5 million as its ventilator patient count jumped 35%. Meanwhile, gross margin expanded 44%, suggesting that its cost structure and competitive position are also improving. That performance is especially impressive given Viemed’s rock-solid balance sheet.
Looking forward, management expects Q3 revenue growth of about 33% on similar margins.
The stock isn’t dirt cheap after the monstrous run-up. But at a forward P/E of 24, Viemed’s solid growth prospects remain priced very reasonably.